Jimmy P. Xu
Drexel University
Small moleculeChemistryRandom hexamerCapsidLigand efficiency
What is this?
Publications 3
#1Jimmy P. XuH-Index: 2
#2Ashwanth FrancisH-Index: 1
Last. Simon CocklinH-Index: 19
view all 8 authors...
2 Citations
#1Jimmy P. Xu (Drexel University)H-Index: 2
#2Jeffrey D. Branson (Drexel University)H-Index: 1
Last. Simon Cocklin (Drexel University)H-Index: 19
view all 4 authors...
The HIV-1 CA protein is an attractive therapeutic target for the development of new antivirals. An inter-protomer pocket within the hexamer configuration of the CA, which is a binding site for key host dependency factors, is an especially appealing region for small molecule targeting. Using a field-based pharmacophore derived from an inhibitor known to interact with this region, coupled to biochemical and biological assessment, we have identified a new compound that inhibits HIV-1 infection and ...
3 CitationsSource
Despite the considerable successes of highly active antiretroviral therapy (HAART) for the treatment of HIV/AIDS, cumulative drug toxicities and the development of multidrug-resistant virus necessitate the search for new classes of antiretroviral agents with novel modes of action. The HIV-1 capsid (CA) protein has been structurally and functionally characterized as a druggable target. We have recently designed a novel small molecule inhibitor I-XW-053 using the hybrid structure based method to b...
8 CitationsSource